Pharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025

Bulletin Express03-30

Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year ended 31 December 2025.

The distribution remains subject to approval at the forthcoming annual general meeting. If endorsed, the company expects to complete the dividend payment by the end of August 2026.

Key timetable details—including ex-dividend date, record date, book-closure period, shareholders’ approval date, and applicable exchange rate for Hong Kong-traded shares—will be disclosed in subsequent updates. Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) has been appointed as the share registrar.

The announcement did not specify any withholding-tax arrangement or list any outstanding warrants or convertible securities.

Pharmaron’s board currently comprises nine directors: executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee-representative director Mr. Li Shing Chung Gilbert; non-executive directors Mr. Li Jiaqing and Ms. Wan Xuan; and independent non-executive directors Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170564585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170564585","market":"hk","top_or_hot":-1,"title":"Pharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year ended 31 December 2025.</p>\n<p>The distribution remains subject to approval at the forthcoming annual general meeting. If endorsed, the company expects to complete the dividend payment by the end of August 2026.</p>\n<p>Key timetable details—including ex-dividend date, record date, book-closure period, shareholders’ approval date, and applicable exchange rate for Hong Kong-traded shares—will be disclosed in subsequent updates. Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) has been appointed as the share registrar.</p>\n<p>The announcement did not specify any withholding-tax arrangement or list any outstanding warrants or convertible securities.</p>\n<p>Pharmaron’s board currently comprises nine directors: executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee-representative director Mr. Li Shing Chung Gilbert; non-executive directors Mr. Li Jiaqing and Ms. Wan Xuan; and independent non-executive directors Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Proposes Final Cash Dividend of RMB2 per 10 Shares for FY2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year ended 31 December 2025.</p>\n<p>The distribution remains subject to approval at the forthcoming annual general meeting. If endorsed, the company expects to complete the dividend payment by the end of August 2026.</p>\n<p>Key timetable details—including ex-dividend date, record date, book-closure period, shareholders’ approval date, and applicable exchange rate for Hong Kong-traded shares—will be disclosed in subsequent updates. Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) has been appointed as the share registrar.</p>\n<p>The announcement did not specify any withholding-tax arrangement or list any outstanding warrants or convertible securities.</p>\n<p>Pharmaron’s board currently comprises nine directors: executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee-representative director Mr. Li Shing Chung Gilbert; non-executive directors Mr. Li Jiaqing and Ms. Wan Xuan; and independent non-executive directors Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1170564585","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170564585","pubTimestamp":1774880773,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成拟派发2025财年末期现金股息每10股人民币2元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. released a new announcement on 30 March 2026 proposing a final ordinary cash dividend of RMB2 for every 10 shares (equivalent to RMB0.20 per share) for the financial year ended 31 December 2025.\nThe distribution remains subject to approval at the forthcoming annual general meeting. If endorsed, the company expects to complete the dividend payment by the end of August 2026.\nKey timetable details—including ex-dividend date, record date, book-closure period, shareholders’ approval date, and applicable exchange rate for Hong Kong-traded shares—will be disclosed in subsequent updates. Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) has been appointed as the share registrar.\nThe announcement did not specify any withholding-tax arrangement or list any outstanding warrants or convertible securities.\nPharmaron’s board currently comprises nine directors: executive directors Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei; employee-representative director Mr. Li Shing Chung Gilbert; non-executive directors Mr. Li Jiaqing and Ms. Wan Xuan; and independent non-executive directors Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170564585","isCrawlerRequest":true}